Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.

ABSTRACT:

Purpose

The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC). Hormonal manipulation leads to response in some patients with EC, but resistance derived from PI3K pathway activation has been documented. Targeting mammalian target of rapamycin (mTOR) may overcome endocrine resistance. We conducted a two-institution phase II trial of everolimus and letrozole in women with recurrent EC.

Patients and methods

Patients were considered incurable, had measurable disease, and were treated with up to two prior cytotoxic regimens. Everolimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily. Each cycle consisted of 4 weeks of therapy. Patients were treated until progression, toxicity, or complete resp

SUBMITTER: Slomovitz BM 

PROVIDER: S-EPMC4348638 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature